Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients.
Xiaojuan ZhouLaiyan ZhouZhuoran YaoMeijuan HuangYouling GongBingwen ZouJiang ZhuYongmei LiuFeng PengYan ZhangMin YuYanying LiFeifei NaYijun WuKai KangWeigang XiuXuanwei ZhangLin ZhouYong XuJin WangYan WangXue YangYuanjun WuRui LiYu ZhangZhen Zhou YangZhipeng ZhouJing BaiXin YiRuizhan TongLimei YinChong ChenGabriele NiedermannYou LuJianxin XuePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The findings indicate that the novel SBRT + LDRT + sintilimab therapy is safe and promising in patients with PD-L1-positive, driver gene-negative primary metastatic NSCLC.
Keyphrases
- low dose
- small cell lung cancer
- radiation therapy
- squamous cell carcinoma
- early stage
- radiation induced
- single cell
- cell therapy
- high dose
- genome wide
- open label
- copy number
- locally advanced
- stem cells
- gene expression
- clinical trial
- combination therapy
- randomized controlled trial
- transcription factor
- bone marrow
- mesenchymal stem cells
- brain metastases
- replacement therapy
- genome wide analysis